Enveda has secured $311 million in funding, valuing the AI-driven biotech company at $2 billion. The company is advancing clinical trials for drugs targeting skin conditions and weight maintenance after discontinuing GLP-1 therapies.
The American Customer Satisfaction Index read 76.1 in August 2026, the same score it held in 2015, so United States customer expectations have held flat for eleven years while complaints hit records and the variable that actually moved was tolerance.
Read More
TLDR: Regulated-industry marketers who build neuromarketing capabilities at pre-launch stage convert compliance...
Read More